Increase Bupropion Dose to 150mg Daily
Your patient is on subtherapeutic doses of both medications—the most appropriate adjustment is to increase bupropion to 150mg daily (the minimum therapeutic dose for depression) and consider increasing buspirone to 15-30mg daily in divided doses. The current bupropion dose of 75mg is below the therapeutic range for major depressive disorder, and buspirone at 5mg twice daily (10mg total) is also subtherapeutic for anxiety.
Rationale for Dose Optimization
Bupropion Dosing
- Current dose (75mg) is subtherapeutic: The FDA-approved therapeutic range for bupropion in depression is 150-450mg daily 1
- Target dose: Start with 150mg daily (the minimum effective dose), which can be increased to 300mg daily if needed 2
- Bupropion at 300mg daily has demonstrated efficacy for recurrent major depression 3
- The medication is "activating" and specifically noted to reduce apathy and improve energy levels 2—directly addressing your patient's lack of motivation
Buspirone Dosing
- Current dose (10mg/day total) is subtherapeutic: Therapeutic dosing for anxiety typically requires 20-60mg daily 2
- Target dose: Increase to 15mg twice daily (30mg total), with potential titration to 20mg three times daily (60mg total) if needed 2
- Buspirone takes 2-4 weeks to become effective, so patience is required 2
- Evidence supports buspirone's efficacy in depression with comorbid anxiety at doses up to 90mg/day 4, 5
Evidence Supporting This Approach
Bupropion for Motivation and Task Completion
Bupropion is specifically characterized as "activating" with "possible rapid improvement of energy level" 2. This makes it particularly well-suited for patients presenting with lack of motivation and inability to complete tasks. The dopamine-norepinephrine reuptake inhibition mechanism directly targets the motivational deficits your patient describes 6.
Addressing Anxiety Concerns with Bupropion
While bupropion has historically been viewed with caution in anxious patients 2, recent evidence challenges this concern:
- Low-certainty evidence suggests bupropion provides clinically relevant improvement in anxiety symptoms in adults with MDD 7
- Multiple studies show comparable efficacy to SSRIs for mild-to-moderate anxiety in depressed patients 7, 8
- None of the reviewed studies reported clear signals of anxiety worsening on validated anxiety measures 7
- The "activating" effect can be managed by starting low and titrating slowly 2
Buspirone Augmentation Evidence
Buspirone has demonstrated efficacy both as monotherapy and augmentation:
- 59% response rate when added to SSRIs in treatment-resistant depression 9
- Significant improvement in both anxiety and depressive symptoms in patients with GAD and mild depression 5
- Recent 2025 data shows HAMA scores decreased from 25.2 to 15.4 over 12 weeks with buspirone augmentation 10
- Well-tolerated with only 3.7% adverse event rate 10
Practical Implementation Algorithm
Week 1-2:
- Increase bupropion from 75mg to 150mg daily (take in morning to minimize insomnia risk) 1
- Increase buspirone from 5mg BID to 7.5mg BID (15mg total daily)
- Monitor for anxiety, agitation, or insomnia
Week 3-4:
- If tolerated but insufficient response, increase buspirone to 10mg BID (20mg total)
- Continue bupropion at 150mg
Week 6-8:
- Assess response using standardized measures
- If partial response with good tolerability, consider:
Week 12:
- Full therapeutic trial complete
- If inadequate response (<30% improvement), consider switching strategies per guidelines 11, 12
Critical Safety Considerations
Bupropion Warnings
- Seizure risk: Dose-dependent; do not exceed 300mg daily with XL formulation 1
- Contraindications: Seizure disorder, eating disorders, abrupt benzodiazepine/alcohol discontinuation 1
- Monitor for: Suicidal ideation (especially first weeks), behavioral activation, insomnia 1
- Drug interactions: Inhibits CYP2D6—caution with other antidepressants, antipsychotics, beta-blockers 1
Buspirone Considerations
- Takes 2-4 weeks for anxiolytic effect—counsel patient on delayed onset 2
- Generally well-tolerated; main side effects are dizziness and nausea
- No significant drug interactions with bupropion
- Can be taken with or without food
Why Not Alternative Strategies?
Adding an SSRI: Would be premature before optimizing current regimen. Guidelines support augmentation strategies only after adequate trials of first-line agents 11, 12. Your patient hasn't had a therapeutic trial of either current medication.
Switching entirely: The STAR*D trial showed no significant differences between various switch strategies 11, 12. Optimizing current medications is more conservative and evidence-based before switching.
Combination therapy from guidelines: The evidence you provided focuses on obesity management (naltrexone-bupropion) 3 or pediatric anxiety 13—not applicable to your adult patient with depression/anxiety.
Common Pitfall to Avoid
The most common error is abandoning medications before reaching therapeutic doses. Both bupropion and buspirone are currently at subtherapeutic levels. The 2002 guideline explicitly states that dose increases should occur "every 5 to 7 days until therapeutic benefits or significant side effects become apparent" 2. Your patient deserves an adequate therapeutic trial before considering more complex interventions.